Christophe de Romeuf
7Patents
2h-index
14Co-inventors
44Inventor score
Filing activity: Sep 15, 2003 → May 11, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7713524B2 | Use of ADCC-optimized antibodies for treating low-responder patients | Emerging Cross-Sectional Technologies | 26 | Expired |
| US7541029B2 | Anti-rhesus D monoclonal antibodies | Chemistry; Metallurgy | 3 | Active |
| US11345730B2 | Chimeric protein in the treatment of amyloidosis | Physics | 2 | Active |
| US10611843B2 | Anti-CD303 monoclonal antibodies | Chemistry; Metallurgy | 1 | Active |
| US9718889B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 1 | Active |
| US9109020B2 | Use of ADCC-optimized antibodies for treating weak patients | Emerging Cross-Sectional Technologies | 0 | Active |
| US7595165B2 | Method of measuring activation of effector cells | Physics | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.